Increasing the proportion of cancer patients who are diagnosed in early stage could help decrease the number of cancer-related deaths ([@bib1]). Therefore, national cancer control policies in several countries currently encompass initiatives supporting early detection and diagnosis ([@bib27]; [@bib34]; [@bib10]).

The evidence base supporting these initiatives, however, is complex and heterogeneous ([@bib34]). Markers and measures of the timeliness of diagnosis currently in use include short-term survival ([@bib21]; [@bib19]; [@bib32]), diagnosis after an emergency hospital admission ([@bib23]), and length of time intervals between symptom onset and diagnosis ([@bib24]; [@bib17]; [@bib27]). Stage at diagnosis is an excellent measure of early detection, but UK population-based data regarding this measure are limited. A recent National Audit Office report indicated that the completeness of stage information across English cancer registries is \<40% ([@bib20]).

A better understanding of socio-demographic variation in stage at diagnosis could help stratify and tailor symptom awareness and early diagnosis interventions aimed at specific patient groups. We distinguish between 'stratification\' that is, the targeting of an intervention to patient populations at a higher risk and 'tailoring\', that is, the adaptation (or customising), a generic intervention to make its application more suitable for specific patient groups. An example of this concept relates to targeted interventions to increase breast cancer symptom awareness amongst older women ([@bib14]). It can also help focus early diagnosis audit efforts ([@bib33]) towards the cancers and patient groups with greatest potential for improvement.

Against this background, we have set out to examine socio-demographic variation in stage at diagnosis for female breast and lung cancers (two common cancers responsible for about 30% of all cancer diagnoses and cancer deaths in England ([@bib22]) during a recent period.

Materials and methods
=====================

Data
----

We analysed information on the stage at diagnosis of East of England patients diagnosed with female breast ('breast\' hereafter) and lung cancer during the 4-year period 2006--2009 (International Classification of Diseases (ICD)-10 codes C50 and C34, respectively). The study period was chosen as the most recent for which data were available at the time of analysis. Anonymous data were extracted from the Eastern Cancer Registration and Information Centre (ECRIC), a population-based cancer registry covering a general population of ∼5.7 million. The Registry has excellent performance as indicated by conventional measures of cancer registration quality such as death-certificate only registrations (∼0%) and, uniquely at present among other English cancer registries, it holds information on stage at diagnosis for a particularly high proportion of patients ([@bib20]). Stage at diagnosis was classified using the 5th edition of the TNM classification, comprising stages I--IV ([@bib38]). Stage at diagnosis was assigned by CHB and BR, integrating clinical, imaging and pathological information. Patient socioeconomic status was ascribed using the income domain of the Index of Multiple Deprivation (IMD) 2004 deprivation score of the Lower Super Output Area (LSOA) of patients\' residence in order to define quintile groups (1=least deprived, or 'most affluent\' 5=most deprived) ([@bib26]). The income domain of IMD 2004 incorporates information on the proportion of residents of a small area who live in households receiving state-funded support (for example, in the form of income support, unemployment benefit and tax credits). Tumour histological type was categorised into seven groups for breast (infiltrating ductal carcinoma, lobular carcinoma, mixed ductal lobular, other adenocarcinoma, other specified carcinoma, specified not carcinoma tumours and other unspecified) and eight for lung cancer (adenocarcinoma, squamous cell carcinoma, other non-small cell, small cell carcinoma, large cell carcinoma, carcinoid, other specified and other unspecified), using appropriate ICD-Oncology morphology codes ([@bib40]).

Analysis
--------

We aimed to examine socio-demographic variation in advanced stage at diagnosis.

Initial analysis was confined to patients with known stage (complete case analysis). Binary logistic regression was used, defining advanced stage at diagnosis both as diagnosis in stages III/IV, or alternatively as diagnosis in stages II--IV (that is, diagnosis other than in stage I). For brevity, we present findings regarding variation in diagnosis in stages III/IV (*vs* I--II) in the main paper and append analysis relating to diagnosis at stage I (*vs* II--IV). We considered, but did not use, ordinal logistic regression because initial analysis provided evidence of violation of the proportional odds assumption.

Mixed-effects logistic regression models were used to predict advanced stage at diagnosis, adjusting for age group, deprivation quintile and tumour type (both cancers), sex (lung cancer) and screening detection status (breast cancer) as fixed effect categorical variables and including a random effect for Primary Care Trust. Although the UK government plans to abolish Primary Care Trusts in the future, they were responsible for planning, purchasing and quality assuring preventive services and primary or specialist health care for their residents during the study period (2006--2009). A model using only fixed effect variables for patient characteristics would assume that all observations are independent. In reality, patients within the same organisation may be more similar. Therefore, the models used recognise the hierarchical nature of the data, with patient-level observations being nested within Primary Care Trusts. Therefore, they provided information about patient-level variation (for example, between patients of different age, sex or deprivation status) without the risk of identifying spurious associations arising from potential clustering of different patient subgroups in Primary Care Trusts with higher or lower rates of advanced stage at diagnosis. To explore a potential interaction between age and sex for lung cancer, we have included in a subsequent model an interaction variable for age category (continuous) by sex.

Significance testing was principally based on joint log likelihood ratio tests. We specifically focused aspects of the analysis on patients aged \>70 years of age because in recent decades improvements in cancer survival in this age group were smaller compared with those observed in younger patients, a finding thought to partially reflect relatively more advanced stage at diagnosis amongst older patients ([@bib30]). Therefore, in addition to testing the overall effect of age, we also examined the significance of differences between patients ⩾70 years compared with patients in all other age groups. Further, tests for linear trend were used to examine the significance of deprivation group gradients by treating deprivation quintile as continuous rather than a categorical variable.

### Sensitivity analysis

Complete case analysis may be biased, depending on the mechanism responsible for missing data, that is, if data are not 'missing completely at random\' (MCAR) ([Appendix Table A1](#app1){ref-type="app"}). ([@bib39]). Therefore, in addition, we have used two different sensitivity analysis approaches for handling potential bias arising from missing stage information, bearing in mind different assumptions about the potential mechanisms generating missing data.

First, we used multiple imputation to impute stage. Multiple imputation is a method increasingly used in the context cancer epidemiological studies ([@bib15]; [@bib25]; [@bib3]). It assumes that data are 'missing at random\' (MAR), that is, that any systematic differences between the missing and observed values can be estimated using information from the observed data (note: the MAR assumption does not mean that there are no systematic associations between missing data and specific variables) ([Appendix Table A1](#app1){ref-type="app"}). We included in imputation models survival, tumour histological grade, basis of diagnosis (that is, whether the diagnosis was verified with histology or not), Primary Care Trust and oestrogen receptor status (breast cancer imputation models only) in addition to all the variables used in the analysis models. All exposure variables used in either the analysis or imputation models were complete, except for grade and oestrogen receptor status (used in imputation models).

Second, as it is not possible to verify the MAR assumption empirically, we conducted sensitivity analysis with a more extreme imputation of missing stage that falls under the assumption of data 'missing not at random\' (MNAR) ([Appendix Table A1](#app1){ref-type="app"}). To do this, we assigned all patients with unknown stage to the advanced stage category (III/IV), and repeated the analysis. This extreme case scenario approach is based on observations that the survival of patients with missing stage information is typically similar to that of patients diagnosed in advanced stage ([@bib13]). We do not expect this extreme case scenario to represent a true situation, but we use it to illustrate how sensitive the complete case and multiple imputation analyses may be to the MCAR or MAR assumptions, respectively. All analysis was conducted in STATA 11 (StataCorp. 2009, College Station, TX, USA), including using the *ice* and *mim* commands used for multiple imputation ([@bib36]). Further details are provided in [Appendix Table A1](#app1){ref-type="app"}.

Results
=======

Data relate to 17 836 and 13 286 patients with incident diagnosis of breast and lung cancer. Information on stage at diagnosis was complete for 16 460 (92%) and 10 435 (79%) patients. The completeness of stage information varied substantially between patients with different socio-demographic characteristics and tumour types -- missing stage was more frequent in older patients in particular (*P*\<0.001 for both cancers, [Appendix Table A2](#app1){ref-type="app"}). Among staged patients with breast and lung cancer, 41% and 15% were diagnosed in stage I, and 86% and 21% in stages I/II, respectively ([Table 1](#tbl1){ref-type="table"}).

Multivariate complete case analysis
-----------------------------------

### Breast cancer

There was very strong evidence of an association between age and diagnosis in stages III/IV, ([Table 2](#tbl2){ref-type="table"}). Specifically for women aged ⩾70 years, the frequency of diagnosis in stages III/IV increased progressively with older age (odds ratios (ORs): 1.21, 1.46, 1.68 and 1.78 for women aged 70--74, 75--79, 80--84 and ⩾85 years, respectively, *P*\<0.001). Increasing deprivation was associated with a greater frequency of stage III/IV diagnosis (joint log likelihood ratio *P*=0.010, p for trend=0.002; [Table 2](#tbl2){ref-type="table"}).

### Lung cancer

There was very strong evidence of an association between age and advanced stage at diagnosis ([Table 3](#tbl3){ref-type="table"}). The frequency of stage III/IV diagnosis decreased progressively among patients aged ⩾70 years (ORs: of 0.82, 0.74, 0.73 and 0.66 for patients aged 70--74, 75--79, 80--84 and ⩾85 years, respectively, *P*\<0.001). There was no evidence for deprivation group differences in lung cancer diagnosis at stages III/IV, in spite of an apparent trend towards lower frequency with increasing deprivation (p for trend=0.236) ([Table 3](#tbl3){ref-type="table"}). There was strong evidence of a higher frequency of advanced stage at diagnosis in men (odds ratio of 1.14 for diagnosis in stages III/IV, *P*=0.011). There was no evidence for a differential effect of age in men and women (OR for men *vs* women per increase in age group category=0.96, 95% CI 0.92--1.01, *P*=0.100). Although this may reflect lack of power, the size of the interaction indicates that a large synergistic effect is unlikely.

Examining variation in diagnosis in stage I *vs* II--IV produced overall similar findings for lung cancer. For breast cancer, the findings were similar in respect of variation in older age, but there was no evidence of deprivation differences ([Appendix Tables A3 and A4](#app1){ref-type="app"}).

### Sensitivity analysis

Repeating the analysis using multiple imputation of missing stage information produced highly similar values and patterns to those derived by the complete case analysis ([Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}). Specifically, for both breast and lung cancer the same patterns of variation by age, deprivation and sex (for lung cancer only) were apparent. Repeating the analysis using the extreme case scenario approach (missing stage=advanced stage) produced similar patterns of variation for lung cancer. For breast cancer, in the extreme case scenario that the true stage at diagnosis of all women with missing information was either stage III or IV, deprivation differences in advanced stage at diagnosis would be smaller. The full output from all analysis models is provided in [Appendix Table A5](#app1){ref-type="app"}.

Discussion
==========

Summary of findings and comparisons with other literature
---------------------------------------------------------

Using population-based data, we identified substantial socio-demographic variation in the stage at diagnosis of breast and lung cancer. Breast cancer patients who were ⩾70 years of age had a higher frequency of advanced stage at diagnosis. Conversely, age ⩾70 was associated with a lower frequency of advanced stage at diagnosis for lung cancer. Advanced stage at diagnosis was more frequent in more deprived patients with breast cancer. Men with lung cancer had a higher frequency of advanced stage at diagnosis. The findings were robust to multiple imputation of missing stage (under the MAR assumption). Similar patterns of variation were also observed for extreme case scenario analysis (under the MNAR assumption of missing stage=advanced stage), except that deprivation differences in advanced stage diagnosis for breast cancer were smaller.

Regarding age differences in stage at diagnosis, no apparent age patterns were apparent in a recent analysis of the US breast cancer data ([@bib8]). For lung cancer, evidence from Denmark indicates a lower frequency of advanced stage at diagnosis with increasing age, as observed in our own study ([@bib12]).

For breast cancer, the observed socioeconomic differences concord with other evidence from the United Kingdom, United States and Canada, indicating a higher frequency of advanced stage at diagnosis among women of lower socioeconomic position. ([@bib2]; [@bib9]; [@bib11]; [@bib5]). For lung cancer, studies from Canada, Denmark and Sweden have indicated only limited socioeconomic differences in advanced stage at diagnosis ([@bib4]; [@bib5]; [@bib12]). A previous UK study reported lower frequency of advanced stage at diagnosis in more deprived patients ([@bib6]). The findings of our study are similar with previous UK research, although there was no independent evidence of an association (*P* for trend=0.236) that may reflect the lack of power.

Strengths and limitations
-------------------------

The principal strengths of the study are its population-based design, and the high quality and completeness of information on stage at diagnosis and other tumour variables. Unlike previous studies in this field, we adjusted the analysis for tumour subtype and employed sensitivity analyses approaches using different assumptions about potential mechanisms responsible for missing stage data. Previous studies on stage at diagnosis of breast cancer did not encompass adjustment for screening or symptomatic detection status, and this factor complicated the interpretation of age and socioeconomic differences in stage at diagnosis ([@bib18]; [@bib2]; [@bib11]). In contrast, our findings indicate that substantial age and deprivation differences in stage at diagnosis of breast cancer exist independently of whether a woman was diagnosed by screening or after symptomatic presentation. A previous UK study on stage at diagnosis of lung cancer only reported on socioeconomic differences (not encompassing age and sex differences) in the mid-1990s ([@bib6]). Therefore, we believe the findings enrich substantially the currently available evidence on patterns of stage at diagnosis in patients with breast and lung cancer.

The study also has certain limitations. We could not adjust the analysis for ethnicity -- a potential confounder of deprivation in particular. During the study period, the proportion of East of England residents belonging to ethnic minorities was relatively small, particularly among persons ⩾65 years (where the majority of cancer cases occur); ∼97% of the East of England resident population in this age group were estimated as being British White in 2007 ([@bib28]). Given the demographic characteristics of the East of England population, the findings can be considered to chiefly describe socio-demographic variation in stage at diagnosis among White British patients. Nevertheless, examination of patterns of stage at diagnosis by ethnic group is warranted in the future.

We examined data from a single region that includes about 10% of the total English population. Socioeconomic differences in short-term cancer survival, however, (a marker of early diagnosis) are relatively similar across different English regions ([@bib32]). Inequalities in cancer treatment patterns observed in East of England cancer patients are also similar to those observed nationwide ([@bib41]). These considerations indicate that the observed socio-demographic patterns of stage at diagnosis can be applicable to the rest of the English population. The size of the East of England population (∼5.7 million) is similar to that of several European countries.

In common with previous authoritative UK research ([@bib6]; [@bib2]; [@bib31]), we used an area-based measure of socioeconomic status in our study, relating to the population characteristics of highly homogeneous small areas (LSOA) ([@bib42]). Socioeconomic status can be measured either directly (for example, by measuring a person\'s income, occupation or education) or indirectly (ecologically) by measuring the characteristics of the population of a small area ([@bib16]). Both direct and area-based measures of socioeconomic status have limitations ([@bib37]), and might be affected by lack of homogeneity within groups (for example, between patients of the same social class, income, education or neighbourhood) ([@bib7]). Using an area-based measure of socioeconomic status may have either underestimated or overestimated socioeconomic gradients in stage at diagnosis compared with direct measures ([@bib37]), and research examining such gradients using both area-based and direct measures would be useful.

Interpretation and research policy implications
-----------------------------------------------

A key consideration in interpreting the findings is whether the observed variation in advanced stage at diagnosis, particularly in relation to age, can be considered avoidable. In theory, the findings might in part reflect differences in the malignant potential of tumours between patients of different ages. The analysis was, however, adjusted for tumour subtype. This makes it less likely that age differences in tumour biology can be responsible for major part of the observed age differences in stage at diagnosis.

For breast cancer, it is possible that the observed variation in stage at diagnosis reflects differences in the awareness of cancer symptoms between different patient groups. Awareness of cancer symptoms and signs in the United Kingdom is socio-demographically patterned, and is lower among individuals aged \>65 and of lower socioeconomic status ([@bib35]). The findings of the study would support the targeting of breast cancer awareness interventions at older women ([@bib14]).

The lower frequency of advanced stage at diagnosis among older lung cancer patients could reflect more frequent use of chest *X* ray investigations in older patients (for example, in the context of investigating either a chest infection or other clinical presentations such as shortness of breath). A recent population study from Denmark indicated a lower frequency of advanced stage lung cancer diagnosis among patients with higher levels of comorbidity and also (as observed in our study) with increasing age ([@bib12]). Another potential explanation is that 'stage for stage\' lung cancer is more symptomatic in older patients, for example, either because of a higher propensity to present with concomitant chest infection (prompting earlier investigation and leading to earlier diagnosis) or earlier presentation of dyspnoea because of physiologically declining lung capacity in older age. Further research in this area is clearly needed to explore the validity of these hypotheses, and to identify the mechanisms responsible for excess risk of advanced stage at diagnosis in relatively younger patients.

There was a substantial excess risk of advanced stage at diagnosis among breast cancer women ⩾70 years of age. These differences should not be dismissed as clinically unimportant; in our study sample, one-third of women with breast cancer were aged ⩾70 years. In the United Kingdom, life expectancy for women aged 70 and 80 year-old is 16.5 and 9.5 years, respectively ([@bib29]). Decreasing the frequency of advanced stage at diagnosis among women ⩾70 years can therefore contribute substantially to reducing avoidable mortality in this age group. In contrast, the findings also identify opportunities for achieving earlier stage diagnosis of lung cancer in relatively young patients (for example, those aged 60--74 years).

Conclusion
==========

There is substantial potential for improvements in early diagnosis in older patients with breast cancer and in relatively younger patients with lung cancer. The findings could help guide breast and lung cancer early diagnosis initiatives and research focused on individuals of different age groups at highest risk of advanced stage at diagnosis. These could, for example, encompass age stratified and tailored cancer symptoms awareness interventions, or educational interventions for physicians and healthcare professionals, targeted at patients of different age groups. We provide an exemplar of how population-based cancer registration information could help support national initiatives aimed at improving early diagnosis, and inform further policy and research.

We thank all staffs of the Eastern Cancer Registration and Information Centre and Dr David Gilligan for his insightful comments regarding older age advanced stage diagnosis patterns for lung cancer. GL is funded by a Post-Doctoral Research Fellowship award from the National Institute for Health Research.

Further details on imputation
=============================

We used the STATA *ice* command for multiple imputation (see reference by [@bib36] of main paper). For (female) breast cancer, imputation models included information on age, deprivation, tumour type, screening detection status, tumour grade, oestrogen receptor status, histological verification status, Primary Care Trust and survival. For lung cancer, imputation models included information on age, sex, deprivation, tumour type, tumour grade, histological verification status and Primary Care Trust and survival.

Stage was treated as a binary variable (stage III/IV *vs* I/II). Grade was treated as an ordinal variable with four levels for colorectal and lung cancer, and three levels for breast cancer. All other variables except for survival were treated as categorical. For survival we used the Nelson--Aalen estimate of the cumulative hazard function along with an indicator variable describing vital status at end of follow-up.

Informed by considerations of the proportion of missing data for different variables, 50 imputed data sets were generated for either cancer. All imputed data sets were each analysed separately and then combined using Rubin\'s rules, using the STATA *mim* command.

Analysis models on the imputed data sets included the same variables as those used in the analysis models using the complete case analysis approach, that is, age, deprivation, tumour type and screening detection status for breast cancer, and age, sex, deprivation and tumour type for lung cancer, including a random effect for Primary Care Trust.
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###### Proportion of patients by stage, gender, age and deprivation group categories for breast and lung cancer (2006--2009)

                                           **Breast**   **Lung**                      
  ---------------------------------------- ------------ ---------- ----- ------ ----- -----
  *Stage*                                                                             
   Stage I                                 6788         38%        41%   1534   12%   15%
   Stage II                                7361         41%        45%   670    5%    6%
   Stage III                               1490         8%         9%    3483   26%   33%
   Stage IV                                821          5%         5%    4748   36%   46%
   Unknown                                 1376         8%         n/a   2851   21%   n/a
                                                                                       
  *Sex*                                                                               
   Men                                     n/a                           7684   58%    
   Women                                   17 836       100%             5602   42%    
                                                                                       
  *Age group*[a](#t1-fn1){ref-type="fn"}                                              
   15--39                                  770          4%                             
   40--44                                  1091         6%               n/a           
   45--49                                  1539         9%                             
   15--49                                  n/a                           380    3%     
   50--54                                  2048         11%              443    3%     
   55--59                                  1911         11%              903    7%     
   60--64                                  2461         14%              1525   11%    
   65--69                                  2152         12%              1762   13%    
   70--74                                  1491         8%               2166   16%    
   75--79                                  1590         9%               2384   18%    
   80--84                                  1321         7%               2099   16%    
   ⩾85                                     1462         8%               1624   12%    
                                                                                       
  *Deprivation group*                                                                 
   Affluent                                4778         27%              2471   19%    
   2                                       4658         26%              3072   23%    
   3                                       4323         24%              3444   26%    
   4                                       3081         17%              3072   23%    
   Deprived                                996          6%               1227   9%     

Younger age groups were categorised differently for the two examined cancers because compared with breast cancer there were fewer patients with lung cancer in the younger age groups.

###### Breast cancer. Independent associations of age and deprivation with advanced stage at diagnosis (i.e., stage III/IV *vs* stage I/II)[a](#t2-fn1){ref-type="fn"} (*n*=16 460)

                  **Odds ratio**   **Lower 95% confidence interval**   **Higher 95% confidence interval**   ***P***
  --------------- ---------------- ----------------------------------- ------------------------------------ -------------------------------------------------------------------------
  15--39          1.15             0.89                                1.48                                  
  40--44          1.02             0.81                                1.28                                  
  45--49          0.91             0.74                                1.14                                  
  50--54          0.92             0.74                                1.14                                  
  55--59          0.90             0.72                                1.12                                  
  60--64          0.91             0.74                                1.12                                  
  65--69          Reference                                                                                 \<0.001[b](#t2-fn2){ref-type="fn"} (\<0.001)[c](#t2-fn3){ref-type="fn"}
  70--74          1.21             0.98                                1.49                                  
  75--79          1.46             1.20                                1.78                                  
  80--84          1.68             1.37                                2.07                                  
  ⩾85             1.78             1.45                                2.18                                  
  Most affluent   Reference                                                                                 0.010[b](#t2-fn2){ref-type="fn"} (0.002)[d](#t2-fn4){ref-type="fn"}
  2               1.16             1.02                                1.32                                  
  3               1.12             0.98                                1.28                                  
  4               1.29             1.12                                1.49                                  
  Deprived        1.23             1.00                                1.52                                  

From logistic regression models, with stage III/IV *vs* stage I/II diagnosis as the binary outcome variable. Models were adjusted for age, deprivation, tumour type and diagnosis through screening or symptomatically, and included a random effect for Primary Care Trust.

From joint log likelihood test for effect of age or deprivation as applicable.

From joint log likelihood ratio tests for significance of difference between patients aged ⩾70 years and patients in all other age groups.

From models with deprivation quintile group entered as a continuous variable.

###### Lung cancer. Independent associations of age, deprivation and sex with advanced stage diagnosis (i.e., stage III/IV *vs* stage I/II)[a](#t3-fn1){ref-type="fn"} (*n*=10 435)

                   **Odds ratio**  **Lower 95% confidence interval**   **Higher 95% confidence interval**                                    ***P***
  --------------- ---------------- ----------------------------------- ------------------------------------ -------------------------------------------------------------------------
  Women              Reference                                                                                                  0.011[b](#t3-fn2){ref-type="fn"}
  Men                   1.14       1.03                                1.25                                                                      
  15--49                1.33       0.93                                1.90                                  \<0.001[b](#t3-fn2){ref-type="fn"} (\<0.001)[c](#t3-fn3){ref-type="fn"}
  50--54                1.00       0.74                                1.35                                                                      
  55--59                1.26       0.99                                1.61                                                                      
  60--64                0.96       0.79                                1.18                                                                      
  65--69             Reference                                                                                                                   
  70--74                0.82       0.68                                0.97                                                                      
  75--79                0.74       0.62                                0.88                                                                      
  80--84                0.73       0.61                                0.88                                                                      
  ⩾85                   0.66       0.54                                0.81                                                                      
  Most affluent      Reference                                                                                0.290[b](#t3-fn2){ref-type="fn"} (*0.236*)[d](#t3-fn4){ref-type="fn"}
  2                     0.94       0.81                                1.09                                                                      
  3                     0.97       0.83                                1.12                                                                      
  4                     0.98       0.84                                1.14                                                                      
  Deprived              0.81       0.66                                0.99                                                                      

From logistic regression models, with stage II--IV *vs* stage I or stage III/IV *vs* stage I/II diagnosis as the binary outcome variable. Models were adjusted for age, sex, deprivation and tumour type, and included a random effect for Primary Care Trust.

From joint log likelihood test for effect of sex, age or deprivation as applicable.

From joint log likelihood ratio tests for significance of difference between patients aged ⩾70 years and patients in all other age groups.

From models with deprivation quintile group entered as a continuous variable.

###### Breast cancer. Summary of outputs obtained by complete case analysis and sensitivity analyses (odds ratios for stage III/IV *vs* I/II).

                  **Complete case analysis**[a](#t4-fn1){ref-type="fn"}   **Multiple imputation**   **Missing stage=II--IV**
  --------------- ------------------------------------------------------- ------------------------- --------------------------
  15--39          1.15                                                    1.13                      1.08
  40--44          1.02                                                    1.01                      0.85
  45--49          0.91                                                    0.91                      0.85
  50--54          0.92                                                    0.90                      0.93
  55--59          0.90                                                    0.88                      0.81
  60--64          0.91                                                    0.90                      0.86
  65--69          Reference                                                                          
  70--74          1.21                                                    1.23                      1.08
  75--79          1.46                                                    1.49                      1.30
  80--84          1.68                                                    1.74                      1.77
  ⩾85             1.78                                                    1.84                      2.21
  Most affluent   Reference                                                                          
  2               1.16                                                    1.20                      1.12
  3               1.12                                                    1.16                      1.07
  4               1.29                                                    1.32                      1.21
  Deprived        1.23                                                    1.27                      1.07

This column replicates information included in Table 2 -- presented here for ease of comparisons.

###### Lung cancer. Summary of outputs obtained by complete case analysis and sensitivity analyses (odds ratios for stage III/IV *vs* I/II)

                   **Complete case analysis**[a](#t5-fn1){ref-type="fn"}  **Multiple imputation**   **Missing stage=stage II--IV**
  --------------- ------------------------------------------------------- ------------------------- --------------------------------
  Women                                  Reference                                                   
  Men                                      1.14                           1.13                      1.15
  15--49                                   1.33                           1.23                      1.31
  50--54                                   1.00                           0.96                      0.95
  55--59                                   1.26                           1.22                      1.23
  60--64                                   0.96                           0.95                      0.95
  65--69                                 Reference                                                   
  70--74                                   0.82                           0.80                      0.82
  75--79                                   0.74                           0.72                      0.75
  80--84                                   0.73                           0.73                      0.78
  ⩾85                                      0.66                           0.68                      0.76
  Most affluent                          Reference                                                   
  2                                        0.94                           0.97                      0.95
  3                                        0.97                           1.01                      0.97
  4                                        0.98                           1.04                      0.99
  Deprived                                 0.81                           0.91                      0.82

This column replicates information included in Table 3 -- presented here for ease of comparisons.

###### Additional details on methods of sensitivity analysis and imputation. Potential mechanisms responsible for missing stage data

  **Assumed mechanism**                                                                                                                                                                                                                                                                                                                                                                                                                                                              **How each assumption relates to the analysis in this paper**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \'Missing completely at random\' (MCAR): there are no systematic differences between the missing values and the observed values.                                                                                                                                                                                                                                                                                                                                                   'Complete case analysis\' will give unbiased (although less precise) estimates under the MCAR assumption. Said differently, complete case analysis implicitly assumes that data are 'missing completely at random\'. Although this assumption does not hold (we know that stage is more likely to be missing in older patients), the potential for bias is minimised by the high level of stage data completeness.
  'Missing at random\' (MAR): any systematic difference between the missing and observed values can be explained by differences in observed data. Under this assumption, although patients with missing stage information may have a higher probability of being diagnosed in advanced stage compared with patients with observed stage, this probability can be estimated from the associations of stage with age, sex, tumour type and so on among patients with observed stage.   The assumption that stage data are 'missing at random\' underpins sensitivity analysis using multiple imputation. This assumption becomes more reasonable by also including in imputation models variables other than those used in the analysis models (e.g., survival, grade and basis of diagnosis).[a](#ta1-fn1){ref-type="fn"}
  'Missing not at random\' (MNAR): even after information from patients with observed stage and its associations with other variables are taken into account, systematic differences remain between patients with missing and observed stage. For example, because more advanced stage at diagnosis is more likely to remain unobserved.                                                                                                                                             The assumption that stage data are 'missing not at random\' underpins sensitivity analysis using substitution of unknown stage values with advanced stage. We do not expect this extreme case scenario to be true, but it illustrates how sensitive the complete case and multiple imputation analyses may be to the MCAR or the MAR assumptions, respectively.

When only outcome data are missing (e.g., on patient stage), complete case analysis will give unbiased estimates under the assumption that data are 'missing at random\' when the missing outcome is dependent only on variables included in the analysis model. This assumption is more reasonable than the 'missing completely at random\' one, but may still not hold; however, it can become even more reasonable by including additional variables in the imputation models, as applied in this study.

###### Predictors of missing stage

                                   **Total**   **Staged**   **% staged**   ***p* (*χ*^2^)**
  -------------------------------- ----------- ------------ -------------- -------------------------------------
  *(a) Breast cancer*                                                       
   Affluent                        4778        4385         92             0.490[a](#ta2-fn1){ref-type="fn"}
   2                               4658        4321         93              
   3                               4323        4007         93              
   4                               3081        2809         91              
   Deprived                        996         938          94              
   15--39                          770         709          92             \<0.001[b](#ta2-fn2){ref-type="fn"}
   40--44                          1091        1036         95              
   45--49                          1539        1437         93              
   50--54                          2048        1930         94              
   55--59                          1911        1832         96              
   60--64                          2461        2350         95              
   65--69                          2152        2036         95              
   70--74                          1491        1393         93              
   75--79                          1590        1458         92              
   80--84                          1321        1133         86             \<0.001[c](#ta2-fn3){ref-type="fn"}
   ⩾85                             1462        1146         78              
   Infiltrating ductal carcinoma   12 826      12 030       94             \<0.001[b](#ta2-fn2){ref-type="fn"}
   Lobular carcinoma               2099        1922         92              
   Mixed ductal lobular            1211        1164         96              
   Other adenocarcinoma            709         653          92              
   Other specified carcinoma       89          79           89              
   Other unspecified               863         609          71              
   Specified not carcinoma         39          3            8               
   All patients                    17 836      16 460       92              
  *(b) Lung cancer*                                                         
   Men                             5602        4392         78             0.736[a](#ta2-fn4){ref-type="fn"}
   Women                           7684        6043         79              
   Affluent                        2471        1900         77             0.009[b](#ta2-fn5){ref-type="fn"}
   2                               3072        2402         78              
   3                               3444        2734         79              
   4                               3072        2397         78              
   Deprived                        1227        1002         82              
   15--49                          380         287          76             \<0.001[a](#ta2-fn4){ref-type="fn"}
   50--54                          443         359          81              
   55--59                          903         743          82              
   60--64                          1525        1248         82              
   65--69                          1762        1416         80              
   70--74                          2166        1759         81              
   75--79                          2384        1899         80              
   80--84                          2099        1597         76             \<0.001[c](#ta2-fn6){ref-type="fn"}
   ⩾85                             1624        1127         69              
   Adenocarcinoma                  2366        1901         80             \<0.001[a](#ta2-fn4){ref-type="fn"}
   Carcinoid                       100         16           16              
   Large cell carcinoma            145         128          88              
   Other non-small cell            2475        2117         86              
   Small cell carcinoma            1464        1150         79              
   Specified other                 10          2            20              
   Squamous cell carcinoma         2351        2040         87              
   Unspecified other               4375        3081         70              
   All patients                    13 286      10 435       79              

^a^From univariate logistic regression for stage completeness, with deprivation quintile group entered as a continuous exposure variable.

From *χ*^2^-test.

From log likelihood ratio tests for significance of difference between the 'older\' age groups (i.e. age groups ⩾70 years) and other age groups.

^a^From *χ*^2^-test.

From univariate logistic regression for stage completeness, with deprivation quintile group entered as a continuous variable.

From log likelihood ratio tests for significance of difference between the 'older\' age groups (i.e., age groups ⩾70 years) and other age groups.

###### Findings in relation to variation in breast cancer diagnosis at stage I *vs* stages II--IV

                    **Stage II-IV *vs* stage I**                 
  ----------------- ------------------------------ ------ ------ ---------------------------------------
  *Breast cancer*                                                 
   15--39           2.04                           1.69   2.47   \<0.001[a](#ta3-fn2){ref-type="fn"}
   40--44           1.67                           1.42   1.96    
   45--49           1.57                           1.35   1.81    
   50--54           1.30                           1.14   1.48    
   55--59           1.23                           1.08   1.41    
   60--64           1.06                           0.93   1.20    
   65--69           Reference                                     
   70--74           1.45                           1.25   1.67   (\<0.001[b](#ta3-fn3){ref-type="fn"})
   75--79           1.70                           1.47   1.97    
   80--84           1.99                           1.69   2.34    
   ⩾85              2.41                           2.04   2.86    
   Most affluent    Reference                                    0.335[a](#ta3-fn2){ref-type="fn"}
   2                1.03                           0.94   1.13   (*0.172*[c](#ta3-fn4){ref-type="fn"})
   3                1.03                           0.94   1.13    
   4                1.11                           1.00   1.24    
   Deprived         1.00                           0.86   1.17    

Independent associations of age and deprivation with diagnosis in stage I *vs* II--IV[d](#ta3-fn5){ref-type="fn"} (*n*=16 460)

From joint log likelihood test for effect of age or deprivation as applicable.

From joint log likelihood ratio tests for significance of difference between patients aged ⩾70 years and patients in all other age groups.

From models with deprivation quintile group entered as a continuous variable.

From logistic regression models, with diagnosis in stage II--IV *vs* stage I as the binary outcome variable. Models were adjusted for age, deprivation, tumour type and diagnosis through screening or symptomatic presentation, and included a random effect for Primary Care Trust.

###### Findings in relation to variation in lung cancer diagnosis at stage I vs stages II--IV

                               **Complete case analysis**   **Multiple imputation**   **Missing stage=stage III/IV**                                              
  ---------------------------- ---------------------------- ------------------------- -------------------------------- ------ ------ ------ ------- ------ ------ -------
  Women                        Ref.                         --                        --                               Ref.   --     --     --      Ref.   --     --
  Men                          1.14                         1.03                      1.25                             1.13   1.03   1.25   0.170   1.15   1.05   1.27
  15--49                       1.33                         0.93                      1.90                             1.23   0.86   1.75   0.197   1.31           
  50--54                       1.00                         0.74                      1.35                             0.96   0.71   1.30   0.157   0.95   0.93   1.84
  55--59                       1.26                         0.99                      1.61                             1.22   0.96   1.55   0.119   1.23   0.71   1.27
  60--64                       0.96                         0.79                      1.18                             0.95   0.78   1.16   0.150   0.95   0.97   1.56
  65--69                       Ref.                         --                        --                               Ref.   --     --     --      --     0.78   1.15
  70--74                       0.82                         0.68                      0.97                             0.80   0.68   0.96   0.109   0.82   0.69   0.98
  75--79                       0.74                         0.62                      0.88                             0.72   0.60   0.86   0.171   0.75   0.64   0.89
  80--84                       0.73                         0.61                      0.88                             0.73   0.61   0.87   0.16    0.78   0.65   0.93
  ⩾85                          0.66                         0.54                      0.81                             0.68   0.55   0.83   0.23    0.76   0.62   0.92
  Most affluent                Ref.                         --                        --                               Ref.   --     --     --      Ref.   --     --
  2                            0.94                         0.81                      1.09                             0.97   0.84   1.12   0.138   0.95   0.82   1.10
  3                            0.97                         0.83                      1.12                             1.01   0.87   1.17   0.184   0.97   0.84   1.12
  4                            0.98                         0.84                      1.14                             1.04   0.89   1.21   0.209   0.99   0.86   1.15
  Deprived                     0.81                         0.66                      0.99                             0.91   0.75   1.10   0.186   0.82   0.67   0.99
  Adenocarcinoma               Ref.                         --                        --                               Ref.   --     --     --      Ref.   --     --
  Squamous cell carcinoma      0.91                         0.79                      1.05                             0.89   0.77   1.02   0.116   0.83   0.72   0.95
  Other non-small cell types   2.07                         1.77                      2.42                             1.97   1.70   2.29   0.099   1.87   1.61   2.18
  Small cell carcinoma         4.06                         3.23                      5.12                             3.90   3.10   4.92   0.207   3.94   3.14   4.94
  Large cell carcinoma         1.51                         0.97                      2.36                             1.44   0.93   2.22   0.065   1.29   0.83   1.99
  Carcinoid                    0.02                         0.00                      0.18                             0.02   0.00   0.15   0.764   1.53   0.87   2.70
  Specified other              0.41                         0.03                      6.63                             0.74   0.06   9.27   0.627   2.30   0.29   18.35
  Unspecified other            1.94                         1.67                      2.24                             1.85   1.59   2.15   0.289   2.07   1.80   2.37

Abbreviations: OR=odds ratio; Ref=reference; LCI=lower confidence interval;

UCI=upper confidence interval; FMI=fraction of missing information (for each respective variable category, it denotes the proportion of the estimation that used imputed missing information).

###### Full outputs of all analysis models presented in main paper (for stage III/IV *vs* I/II comparisons)

                                                                   **Complete case analysis**   **Multiple imputation**   **Missing stage=stage III/IV**                                                 
  ---------------------------------------------------------------- ---------------------------- ------------------------- -------------------------------- ------ ------ ------- ------- ------- ------- --------
  *(a) Breast cancer, stage III/IV *vs* stage I--II*                                                                                                                                                      
   15--39                                                          1.15                         0.89                      1.48                             1.13   0.88   1.46    0.062   1.08    0.87    1.34
   40--44                                                          1.02                         0.81                      1.28                             1.01   0.80   1.27    0.069   0.85    0.70    1.05
   45--49                                                          0.91                         0.74                      1.14                             0.91   0.73   1.13    0.088   0.85    0.70    1.02
   50--54                                                          0.92                         0.74                      1.14                             0.90   0.72   1.11    0.066   0.93    0.78    1.11
   55--59                                                          0.90                         0.72                      1.12                             0.88   0.71   1.09    0.058   0.81    0.67    0.98
   60--64                                                          0.91                         0.74                      1.12                             0.89   0.73   1.10    0.076   0.86    0.72    1.02
   65--69                                                          Ref.                                                                                    Ref.                          Ref.             
   70--74                                                          1.21                         0.98                      1.49                             1.22   0.99   1.50    0.064   1.08    0.90    1.29
   75--79                                                          1.46                         1.20                      1.78                             1.50   1.23   1.82    0.062   1.30    1.09    1.54
   80--84                                                          1.68                         1.37                      2.07                             1.75   1.43   2.15    0.115   1.77    1.49    2.10
   ⩾85                                                             1.78                         1.45                      2.18                             1.86   1.52   2.27    0.128   2.21    1.87    2.62
   Most affluent                                                   Ref.                                                                                    Ref.                          Ref.             
   2                                                               1.16                         1.02                      1.32                             1.20   1.05   1.36    0.107   1.12    1.00    1.25
   3                                                               1.12                         0.98                      1.28                             1.16   1.02   1.32    0.091   1.07    0.95    1.19
   4                                                               1.29                         1.12                      1.49                             1.32   1.15   1.52    0.116   1.21    1.07    1.36
   Deprived                                                        1.23                         1.00                      1.52                             1.27   1.03   1.57    0.149   1.07    0.89    1.29
   Infiltrating ductal carcinoma                                   Ref.                                                                                    Ref.                          Ref.             
   Lobular carcinoma                                               1.59                         1.39                      1.81                             1.62   1.42   1.84    0.061   1.54    1.38    1.73
   Mixed ductal lobular                                            1.09                         0.90                      1.32                             1.10   0.91   1.33    0.051   0.97    0.82    1.15
   Other adenocarcinoma                                            0.99                         0.79                      1.25                             0.98   0.78   1.23    0.058   0.99    0.82    1.20
   Other specified carcinoma                                       0.58                         0.26                      1.26                             0.58   0.27   1.27    0.118   0.90    0.52    1.54
   Other unspecified                                               3.90                         3.26                      4.66                             4.01   3.37   4.77    0.254   4.57    3.93    5.32
   Specified not carcinoma                                         3.57                         0.28                      46.04                            1.78   0.14   22.25   0.870   81.48   19.36   342.93
   Screening detection status- no                                  Ref.                                                                                                                                   
   Screening detection status-yes                                  0.26                         0.22                      0.31                             0.27   0.22   0.32    0.030   0.20    0.17    0.24
  *(b) Lung cancer, odds ratios of stage III/IV *vs* stage I/II*                                                                                                                                          
   Women                                                           Ref.                                                                                    Ref.                          Ref.             
   Men                                                             1.14                         1.03                      1.25                             1.13   1.03   1.25    0.170   1.15    1.05    1.27
   15--49                                                          1.33                         0.93                      1.90                             1.23   0.86   1.75    0.197   1.31             
   50--54                                                          1.00                         0.74                      1.35                             0.96   0.71   1.30    0.157   0.95    0.93    1.84
   55--59                                                          1.26                         0.99                      1.61                             1.22   0.96   1.55    0.119   1.23    0.71    1.27
   60--64                                                          0.96                         0.79                      1.18                             0.95   0.78   1.16    0.150   0.95    0.97    1.56
   65--69                                                          Ref.                                                                                    Ref.                                  0.78    1.15
   70--74                                                          0.82                         0.68                      0.97                             0.80   0.68   0.96    0.109   0.82    0.69    0.98
   75--79                                                          0.74                         0.62                      0.88                             0.72   0.60   0.86    0.171   0.75    0.64    0.89
   80--84                                                          0.73                         0.61                      0.88                             0.73   0.61   0.87    0.16    0.78    0.65    0.93
   ⩾85                                                             0.66                         0.54                      0.81                             0.68   0.55   0.83    0.23    0.76    0.62    0.92
   Most affluent                                                   Ref.                                                                                    Ref.                          Ref.             
   2                                                               0.94                         0.81                      1.09                             0.97   0.84   1.12    0.138   0.95    0.82    1.10
   3                                                               0.97                         0.83                      1.12                             1.01   0.87   1.17    0.184   0.97    0.84    1.12
   4                                                               0.98                         0.84                      1.14                             1.04   0.89   1.21    0.209   0.99    0.86    1.15
   Deprived                                                        0.81                         0.66                      0.99                             0.91   0.75   1.10    0.186   0.82    0.67    0.99
   Adenocarcinoma                                                  Ref.                                                                                    Ref.                          Ref.             
   Squamous cell carcinoma                                         0.91                         0.79                      1.05                             0.89   0.77   1.02    0.116   0.83    0.72    0.95
   Other non-small cell types                                      2.07                         1.77                      2.42                             1.97   1.70   2.29    0.099   1.87    1.61    2.18
   Small cell carcinoma                                            4.06                         3.23                      5.12                             3.90   3.10   4.92    0.207   3.94    3.14    4.94
   Large cell carcinoma                                            1.51                         0.97                      2.36                             1.44   0.93   2.22    0.065   1.29    0.83    1.99
   Carcinoid[a](#ta5-fn2){ref-type="fn"}                           0.02                         0.00                      0.18                             0.02   0.00   0.15    0.764   1.53    0.87    2.70
   Specified other[a](#ta5-fn2){ref-type="fn"}                     0.41                         0.03                      6.63                             0.74   0.06   9.27    0.627   2.30    0.29    18.35
   Unspecified other                                               1.94                         1.67                      2.24                             1.85   1.59   2.15    0.289   2.07    1.80    2.37

Abbreviations: FMI=fraction of missing information (for each respective variable category, it denotes the proportion of the estimation that used imputed missing information); LCI=lower confidence interval; OR=odds ratio; Ref=reference; UCI=upper confidence interval.

For these two groups, large differences are apparent between the analysis under the missing stage**=**stage IV analysis and either complete case analysis or multiple imputation. Both these groups were small and had a particularly small proportion of patients with observed stage (\<20%), most of whom were in stage I/II. The above indicate that the missing stage**=**stage IV assumption for patients with missing stage in these two groups is unlikely to be reasonable; we nevertheless present findings for consistency.
